Academic Content and Language Evaluation of This Article
CrossCheck and Google Search of This Article
Academic Rules and Norms of This Article
Citation of this article
Corresponding Author of This Article
Research Domain of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (3987)
All Articles published online
|
Publishing Process of This Article
|
Aug 14, 2024 (publication date) through Aug 16, 2025
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Gastroenterology
ISSN
1007-9327
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| For: | Xu LX, Yuan JJ, Xue R, Zhou J. Nab-paclitaxel plus capecitabine as first-line treatment for advanced biliary tract cancers: An open-label, non-randomized, phase II clinical trial. World J Gastroenterol 2024; 30(30): 3564-3573 [PMID: 39193574 DOI: 10.3748/wjg.v30.i30.3564] |
|---|---|
| URL: | https://www.wjgnet.com/1007-9327/full/v30/i30/3564.htm |
| Number | Citing Articles |
| 1 |
Chaofan Chen, Jinlei Li, Xiaokun Hua, Tingting Deng, Zhiyun Zhang. Nano-enabled strategies for targeted immunotherapy in gastrointestinal cancers. Frontiers in Immunology 2025; 16 doi: 10.3389/fimmu.2025.1653829
|
| 2 |
Jian-Qiang Chen, Xiang Lan. Nab-paclitaxel plus capecitabine as a first-line regimen for advanced biliary tract cancers: Feasible or not feasible?. World Journal of Gastroenterology 2025; 31(10): 100771 doi: 10.3748/wjg.v31.i10.100771
|